白蛋白结合型紫杉醇在晚期食管癌患者治疗中的应用分析  

Analysis of of albumin-bound paclitaxel in the treatment of advanced esophageal cancer

作　　者：闫晶 李红姬 YAN Jing;LI Hong-ji(Department of Oncology,Jilin People’s Hospital,Jilin 132001,China)

机构地区：[1]吉林市人民医院肿瘤科,132001

出　　处：《中国现代药物应用》2019年第22期119-120,共2页Chinese Journal of Modern Drug Application

摘　　要：目的分析白蛋白结合型紫杉醇在晚期食管癌患者治疗中的治疗效果。方法76例晚期食管癌患者,随机分为研究组和对照组,每组38例。研究组患者采用白蛋白结合型紫杉醇联合顺铂治疗,对照组患者采用常规紫杉醇联合顺铂治疗。比较两组患者治疗结果、不良反应发生情况及治疗后生活质量评分。结果研究组患者治疗总有效率为81.6%,明显高于对照组的60.5%,差异有统计学意义(P<0.05)。研究组患者不良反应发生率为18.4%,低于对照组的39.5%,差异有统计学意义(P<0.05)。治疗后,研究组患者肢体活动、意识情况、社会功能、环境领域评分明显高于对照组,差异具有统计学意义(P<0.05)。结论对晚期食管癌患者实施白蛋白结合型紫杉醇治疗的效果好,且不良反应少,值得在临床上推广。Objective To analyze the therapeutic effect and clinical value of albumin-bound paclitaxel in the treatment of advanced esophageal cancer.Methods A total of 76 patients with advanced esophageal cancer were randomly divided into research group and control group,with 38 cases in each group.The research group was treated by albumin-bound paclitaxel combined with cisplatin,and the control group was treated by conventional paclitaxel combined with cisplatin.The therapeutic effect,occurrence of adverse reactions and quality of life score after treatment was compared in the two groups.Results The total effective rate of treatment was 81.6%in the research group,which was obviously higher than 60.5%in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions was 18.4%,which was lower than 39.5%in the control group,and the difference was statistically significant(P<0.05).After treatment,the scores of physical activity,consciousness,social function and environment field in the research group was obviously higher than those in the control group,and their difference was statistically significant(P<0.05).Conclusion Albumin-bound paclitaxel shows good effect for patients with advanced esophageal cancer,and the adverse reactions are fewer.It is worthy of clinical promotion.

关 键 词：晚期食管癌 白蛋白结合型紫杉醇 紫杉醇 顺铂 

分 类 号：R73[医药卫生—肿瘤]